PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CENTRAL NERVOUS SYSTEM OR LIVER DIS

OPTIMARK 在中枢神经系统或肝病患者中的药理学

• 批准号: 6274324
• 负责人: KENNETH R MARAVILLA
• 金额: $ 2.06万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274324
• 关键词: central nervous system disorders; clinical chemistry; clinical research; dosage; electrocardiography; gadolinium; hematology; human mortality; human subject; human therapy evaluation; iron; liver disorder; liver pharmacology; neuropharmacology; serum; urinalysis; urine; zinc

To evaluate the pharmacologic dose-related effects on vital signs, electrocardiograms, and clinical laboratory measurements (chemistry, hematology, urinalysis, iron and zinc profiles, and gadolinium content in the serum and urine).

为了评价对生命体征的药理学剂量相关影响， 心电图和临床实验室测量（化学， 血液学、尿分析、铁和锌特征以及钆含量 在血清和尿液中）。